Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW To Consider Switch Of 19 Drugs to OTC, Including 12 Hypertension Products

This article was originally published in PharmAsia News

Executive Summary

TOKYO - As a means to reduce national healthcare costs, Japan's Ministry of Health, Labor and Welfare June 7 released 19 pharmaceutical drugs for deliberation by its policy commission as potential switches to over-the-counter pharmaceuticals. The list included 12 hypertension drugs to be sold OTC, believed to be the first time in the world

You may also be interested in...

Japan Paves Way For Pfizer/Wyeth's Viviant To Hit Crowded Osteo Space

The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market

Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market

SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts